Show simple item record

dc.contributor.authorCheng, Socheat
dc.contributor.authorGossop, Michael
dc.contributor.authorKristoffersen, Espen Saxhaug
dc.contributor.authorGrambaite, Ramune
dc.contributor.authorLundqvist, Anders Christofer
dc.date.accessioned2020-08-31T09:10:00Z
dc.date.available2020-08-31T09:10:00Z
dc.date.created2020-07-30T13:11:29Z
dc.date.issued2020
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/11250/2675641
dc.description.abstractObjectives Central nervous system depressants (CNSDs) such as opioids, benzodiazepine and Z-hypnotics are commonly used. However, CNSDs may influence cognitive function, especially in older hospitalised patients with comorbidities. The aim was to examine the association between CNSD use and cognitive function in older patients. We assessed global and domain specific cognitive function, among hospitalised older patients, including covariates for comorbidity, anxiety and depression. Design Cross-sectional hospital-based study. Settings Data was collected consecutively from inpatients at somatic wards of a general university hospital. Participants Older patients between 65 and 90 years with/without CNSD use for ≥4 weeks. Outcome measures The main outcome was cognitive function assessed by Cognistat. Secondary outcomes were routine clinical tests in the wards (mini-mental state examination (MMSE), trail making test (TMT) A and B, and clock drawing tests). Analyses were bivariate and multiple linear regression, adjusted for age, gender, and education. Covariates were comorbidity, depression and anxiety scores. Results The main result indicated that CNSD users (n=100) had (β=–3.4, 95%CI 6.27 to –0.58, p=0.017) lower Cognistat score than non-users (n=146), adjusted for age, gender, education, anxiety and depression, but not significant when including covariate for comorbidity (β= –2.50 - 5.45; –0.46, p=0.097). Comorbidity was associated with cognitive function (β=−0.77, 95%CI −1.22 to −0.14, p=0.014). Cognistat subdimensions associated with CNSD use were language (p=0.017) and calculation (p=0.003). In clock drawing test, users had lower scores than non-users (β=−0.80, 95%CI 1.24 to −0.36, p=0.004), but no significant difference was found with MMSE and TMT A or B. Z-hypnotics were associated with reduced cognitive function. Conclusion Among older hospitalised patients, global cognition and specific cognitive functions were associated with long-term use of CNSD medication as well as with somatic comorbidityen_US
dc.language.isoengen_US
dc.publisherBMJ Openen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAssociation between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.journalBMJ Openen_US
dc.identifier.doi10.1136/bmjopen-2020-038432
dc.identifier.cristin1821052
dc.description.localcodeThis is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal